Roland Buelow
Directeur Général chez TeneoOne, Inc.
Profil
Roland Buelow was the founder of Open Monoclonal Technology, Inc. (founded in 2007) where he served as the Chief Executive Officer from 2007 to 2015.
He was also the founder of TeneoBio, Inc. (founded in 2009) where he held the position of Chief Executive Officer & Director.
Dr. Buelow is also the founder of THP Ltd, Ancora Biotech LLC.
Currently, Dr. Buelow is the Chief Executive Officer at TeneoOne, Inc. and the Director at Medikine, Inc. (since 2022).
In the past, Dr. Buelow worked as the Vice President-Research at SangStat Medical Corp.
from 1993 to 2003.
Postes actifs de Roland Buelow
| Sociétés | Poste | Début |
|---|---|---|
TeneoOne, Inc.
 TeneoOne, Inc. Pharmaceuticals: MajorHealth Technology Part of AbbVie, Inc., TeneoOne, Inc. develops innovative medicines. The CEO of the American company is Roland Buelow. | Directeur Général | - |
Ancora Biotech LLC
 Ancora Biotech LLC BiotechnologyHealth Technology Ancora Biotech LLC is a privately held service provider that supports the clinical development of assets for TeneoTwo, TeneoFour, and TeneoTen, which are all part of TBIO, LLC. The company is based in Palo Alto, CA. Ancora oversees the manufacturing and clinical development of these assets, including TeneoTwo's clinical stage TNB-486, TeneoFour's preclinical TNB-738, and TeneoTen's development of preclinical anti-HBVxCD3 for the treatment of chronic hepatitis B. The company was founded by Roland Buelow. | Fondateur | - |
Medikine, Inc.
 Medikine, Inc. Pharmaceuticals: MajorHealth Technology Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016. | Directeur/Membre du Conseil | 06/12/2022 |
Anciens postes connus de Roland Buelow
| Sociétés | Poste | Fin |
|---|---|---|
Open Monoclonal Technology, Inc.
 Open Monoclonal Technology, Inc. BiotechnologyHealth Technology Open Monoclonal Technology, Inc. engages in the genetic engineering of animals for discovery of human therapeutic antibodies. The firm’s transgenic animal platforms include OmniRat, industry’s first human monoclonal antibody technology based on rats; OmniMouse, a transgenic mouse that complements OmniRat and expands epitope coverage and; OmniFlic, the first engineered rat with a fixed light chain for development of bispecific, fully human antibodies. The company was founded in by Roland Buelow 2007 and is headquartered in San Diego, CA. | Fondateur | 01/01/2015 |
| SangStat Medical Corp. | Directeur Technique/Scientifique/R&D | 01/01/2003 |
TeneoBio, Inc.
 TeneoBio, Inc. Miscellaneous Commercial ServicesCommercial Services TeneoBio, Inc. operates as a biotechnology company that develops biologics, human heavy chain antibodies, as therapeutics against cancer, autoimmunity, and infectious diseases. Its products provides treatment of multiple myeloma, prostate cancer, immune disorders, and AIDS. The company was founded by Roland Buelow, on August 9, 2009 and is headquartered in Menlo Park, CA. | Fondateur | - |
THP Ltd
 THP Ltd Engineering & ConstructionIndustrial Services Part of Graham Holdings Co., THP Ltd is a British company that provides structural and architectural engineering services. The company was founded by Roland Buelow. THP was acquired by Tribeca Learning Pty Ltd., part of Graham Holdings Co. from May 26, 2006 on March 29, 2001. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
| SangStat Medical Corp. | Health Technology |
THP Ltd
THP Ltd Engineering & ConstructionIndustrial Services Part of Graham Holdings Co., THP Ltd is a British company that provides structural and architectural engineering services. The company was founded by Roland Buelow. THP was acquired by Tribeca Learning Pty Ltd., part of Graham Holdings Co. from May 26, 2006 on March 29, 2001. | Industrial Services |
Open Monoclonal Technology, Inc.
Open Monoclonal Technology, Inc. BiotechnologyHealth Technology Open Monoclonal Technology, Inc. engages in the genetic engineering of animals for discovery of human therapeutic antibodies. The firm’s transgenic animal platforms include OmniRat, industry’s first human monoclonal antibody technology based on rats; OmniMouse, a transgenic mouse that complements OmniRat and expands epitope coverage and; OmniFlic, the first engineered rat with a fixed light chain for development of bispecific, fully human antibodies. The company was founded in by Roland Buelow 2007 and is headquartered in San Diego, CA. | Health Technology |
TeneoBio, Inc.
TeneoBio, Inc. Miscellaneous Commercial ServicesCommercial Services TeneoBio, Inc. operates as a biotechnology company that develops biologics, human heavy chain antibodies, as therapeutics against cancer, autoimmunity, and infectious diseases. Its products provides treatment of multiple myeloma, prostate cancer, immune disorders, and AIDS. The company was founded by Roland Buelow, on August 9, 2009 and is headquartered in Menlo Park, CA. | Commercial Services |
Medikine, Inc.
Medikine, Inc. Pharmaceuticals: MajorHealth Technology Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016. | Health Technology |
TeneoOne, Inc.
TeneoOne, Inc. Pharmaceuticals: MajorHealth Technology Part of AbbVie, Inc., TeneoOne, Inc. develops innovative medicines. The CEO of the American company is Roland Buelow. | Health Technology |
Ancora Biotech LLC
Ancora Biotech LLC BiotechnologyHealth Technology Ancora Biotech LLC is a privately held service provider that supports the clinical development of assets for TeneoTwo, TeneoFour, and TeneoTen, which are all part of TBIO, LLC. The company is based in Palo Alto, CA. Ancora oversees the manufacturing and clinical development of these assets, including TeneoTwo's clinical stage TNB-486, TeneoFour's preclinical TNB-738, and TeneoTen's development of preclinical anti-HBVxCD3 for the treatment of chronic hepatitis B. The company was founded by Roland Buelow. | Health Technology |